Shares of HENLIUS (02696) climbed nearly 8% during intraday trading, with the stock last up 6.87% at HK$70.05, recording a turnover of HK$16.47 million. The company recently announced a framework cooperation agreement with global generics and biosimilars leader Sandoz, establishing a strategic partnership covering up to ten monoclonal antibody and/or antibody-drug conjugate (ADC) biosimilar products or components, with specific terms agreed for an initial batch of three products and an option for one additional potential product.

Under the initial agreement, Sandoz will pay Henlius upfront payments, milestone payments, and non-refundable option fees totaling up to US$322 million. In 2026, Henlius expects to invoice no more than US$100.5 million in aggregate. Notably, overseas markets have become a key growth driver for the company's performance. In 2025, Henlius generated revenue of RMB 6.667 billion, up 16.5% year-on-year, with net profit reaching RMB 827 million. Global product revenue hit RMB 5.775 billion, representing a 17.0% increase, while overseas product revenue exceeded RMB 200 million, doubling year-on-year, and overseas product profit reached RMB 94 million.

Where to begin

Investors should monitor the execution of the Sandoz partnership and the ramp-up of overseas product sales, which are pivotal to Henlius's international expansion strategy. The deal's milestone-based payment structure also provides visibility into future cash flows.

Why only a single stock matters here

For those tracking biopharma momentum, Henlius's sharp rally underscores the market's positive reception to licensing deals that validate its biosimilar pipeline. The doubling of overseas revenue highlights the company's successful penetration into global markets, a factor likely to sustain investor interest in the near term.